Merck & Co awaits full Keynote-426 data with Keytruda plus Inlyta, while Seattle Genetics looks beyond Adcetris with enfortumab vedotin.
Others in the FDA queue include Bausch’s psoriasis therapy Duobrii and Motif Bio’s antibiotic Iclaprim.
Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.
Allergan needs a win with rapastinel, while Lundbeck's chief exec faces her second clinical challenge.
Data from quad therapy and a subcutaneous formulation could resuscitate enthusiasm even if the US government shutdown delays Darzalex's upcoming first-line approval.
A limb-girdle muscular dystrophy gene therapy Sarepta licensed last year faces its first clinical test.
Solid Biosciences should soon find out if its DMD gene therapy, SGT-001, could compete with Sarepta’s.
Allergy Therapeutics awaits twice-delayed phase III data on its birch pollen project, while Caladrius Biosciences seeks validation of its Treg approach to type 1…
Jazz wants to expand its sleep portfolio, while Macrogenics hopes trial data will support its first new drug application.